This is the authors' abstract. We don't add key points for this paper.
Antibody-mediated rejection (AMR) has been recognized as a significant cause of acute and chronic lung allograft dysfunction after lung transplantation. Some treatments, eculizumab, an anti-complement (C)5 component monoclonal antibody (Mab), seem to have a promising effect in the management of some patients with AMR. We present two patients with acute AMR after lung transplantation who received the anti-C5 Mab therapy. In both cases, we identified the presence of C4d deposition in the peritubular capillaries on trans-alveolar biopsies, which suggested activation of complement in AMR. Prior to eculizumab therapy, both patients had also received immunoadsorption, courses of intravenous immunoglobulins (IVIG) and rituximab. For the first patient, we have shown that eculizumab can serve as an effective bridge to re-transplantation. For the second patient, we observed the absence of clinical and biological efficacy, and without a clear therapeutic efficacy the therapy with eculizumab had been discontinued after two months. • Eculizumab enabled successful bridging to re-transplantation in a patient with refractory AMR, achieving stable lung function post-transplant. • While eculizumab did not reverse AMR, it stabilized donor-specific antibody levels and prevented further clinical deterioration in one case. • The study highlights the urgent need for validated alternative therapies like eculizumab to improve outcomes in refractory AMR after lung transplantation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mallet et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: